|Bid||73.53 x 800|
|Ask||76.51 x 800|
|Day's Range||73.35 - 74.15|
|52 Week Range||71.65 - 92.57|
|Beta (5Y Monthly)||0.51|
|PE Ratio (TTM)||17.51|
|Earnings Date||Nov 03, 2021 - Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||110.83|
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-08254, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired BioMarin securities between January 13, 2020 and September 3, 2021,
Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) from January 13, 2020 through September 3, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Act of 1934.